Mode of Action | ACEi vs ARBs Hypertension and CV risk 25.06.2026 Mode of Action | ACEi vs ARBs #CVRISK#Hypertension 1
VIDEO | Why Ethical Narratives Matter DiabetesDyslipidaemiaHypertension and CV risk 04.03.2026 VIDEO | Why Ethical Narratives Matter #Diabetes#Dyslipidaemia#Hypertension 4 86
CPD ARTICLE | ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes CPDDiabetes 19.02.2026 CPD ARTICLE | ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Glic... #CPDPoints#Diabetes 3 230
CPD ARTICLE | One Pill or Many? CPDDiabetesHypertension and CV riskPatient Awareness 17.02.2026 CPD ARTICLE | One Pill or Many? #AdherenceMatters#CPDPoints#Diabetes#Hypertension#PatientAwareness 2 192
CPD ARTICLE | Outcomes of People with Type 2 Diabetes using Sulfonylureas versus Other Non-Insulin Antidiabetic Agents during Ramadan: The Diabetes and Ramadan (DaR) Global Surveys. CPDDiabetes 11.02.2026 CPD ARTICLE | Outcomes of People with Type 2 Diabetes using Sulfonylureas versus Other Non-Insulin Antidiabetic Agent... #CPDPoints#Diabetes 1 63
VIDEO | A Triple SPC approach to cardiovascular management CPDHypertension and CV risk 13.11.2025 VIDEO | A Triple SPC approach to cardiovascular management #CPDPoints#CVRISK#Hypertension 1 77
VIDEO | Who’s responsibility is Adherence CPDDiabetesDyslipidaemiaHypertension and CV risk 20.10.2025 VIDEO | Who’s responsibility is Adherence #AdherenceMatters#CPDPoints 60
VIDEO | Glycaemic control: To stay fast or move past CPDDiabetes 14.10.2025 VIDEO | Glycaemic control: To stay fast or move past #CPDPoints#Diabetes 2 75
VIDEO | Reality of Stability CPDHypertension and CV risk 13.10.2025 VIDEO | Reality of Stability #CPDPoints#Hypertension 47
VIDEO | Silencing Cardiovascular disease by amplifying vascular health CPDHypertension and CV risk 13.10.2025 VIDEO | Silencing Cardiovascular disease by amplifying vascular health #CPDPoints#Hypertension 56